menu
    • menu
    [{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"11","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"11","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Sanaria | University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital T\u00fcbingen \/ Sanaria | University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital T\u00fcbingen \/ Sanaria | University of Oxford"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Richmond Pharmacology | PharmaKinetic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines for Malaria Venture \/ Richmond Pharmacology | PharmaKinetic","highestDevelopmentStatusID":"6","companyTruncated":"Medicines for Malaria Venture \/ Richmond Pharmacology | PharmaKinetic"},{"orgOrder":0,"company":"Armaceutica, Inc.","sponsor":"Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyronaridine Tetraphosphate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Armaceutica, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Armaceutica, Inc. \/ Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal","highestDevelopmentStatusID":"8","companyTruncated":"Armaceutica, Inc. \/ Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal"}]

    Find Clinical Drug Pipeline Developments & Deals for Pyronaridine Tetraphosphate

    Menu

    Pyronaridine Tetraphosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mangalam Drugs & Organics Ltd

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Mangalam Drugs & Organics Ltd

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Mangalam Drugs & Organics Awarded US$ 274,800 Grant by MMV

                            Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.

                            Product Name : Pyramax

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 27, 2024

                            Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University Hospital Tübingen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Hospital Tübingen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sanaria | University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Ad...

                            Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2022

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sanaria | University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Armaceutica, Inc.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Armaceutica, Inc.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

                            Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 22, 2022

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Medicines for Malaria Venture

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Richmond Pharmacology | PharmaKinetic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetrapho...

                            Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Richmond Pharmacology | PharmaKinetic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shin Poong Pharm Co Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shin Poong Pharm Co Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections

                            Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2019

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shin Poong Pharm Co Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Shin Poong Pharm Co Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cohort Event Monitoring Study of Pyramax®

                            Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria, Falciparum.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2017

                            Lead Product(s) : Pyronaridine Tetraphosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth